Want to see BMY full AI Analyst Report?
BMY Stock Chart & Stats
$64.72
$0.57(0.89%)
At close: 4:00 PM EDT
$64.72
$0.57(0.89%)
Day’s Range― - ―
52-Week Range$42.52 - $68.64
Previous Close$64.12
Volume7.21M
Average Volume (3M)11.67M
Market Cap
$136.88B
Enterprise Value$151.99K
Total Cash (Recent Filing)$11.07B
Total Debt (Recent Filing)$43.12B
Price to Earnings (P/E)14.8
Beta0.22
Next Earnings
Oct 29, 2026EPS Estimate
1.72Next Dividend Ex-DateN/A
Dividend Yield3.75%
Share Statistics
EPS (TTM)4.54
Shares Outstanding2,042,714,600
10 Day Avg. Volume10,541,143
30 Day Avg. Volume11,673,598
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.96
Price to Sales (P/S)2.28
P/FCF Ratio8.57
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$67.28Price Target Upside3.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)6.93
Revenue Forecast (FY)$49.55B
Bulls Say, Bears Say
Bulls Say
Growth Portfolio ExpansionThe growth portfolio is increasingly offsetting mature-brand erosion, improving the durability of BMS’s revenue base. Broad gains across oncology, immunology and cardiovascular products reduce reliance on any single future launch.
Strong Cash GenerationRobust operating and free cash flow gives BMS capacity to fund research, launches, dividends and debt reduction. High cash conversion also indicates that recent profitability is supported by underlying cash earnings rather than primarily accounting effects.
CELMoD Platform ValidationZenbexus approval creates a commercial entry point for BMS’s CELMoD platform in multiple myeloma. Mezigdomide and other related programs could extend the platform across indications, supporting a potentially meaningful multi-product pipeline.
Bears Say
Elevated Balance-sheet LeverageHigh leverage reduces financial flexibility if product sales weaken or development costs rise. Although debt is improving and cash generation is strong, the capital structure leaves less room to absorb patent losses, clinical setbacks or unexpected regulatory expenses.
Ongoing Legacy Portfolio ErosionGeneric competition and lifecycle pressure will continue removing revenue from established brands. Growth products must expand rapidly enough to replace this base, creating execution risk and potentially limiting overall revenue and margin durability.
Clinical Pipeline Timing RiskDelayed event-driven trials postpone important evidence for potential pipeline assets and extend uncertainty around future growth. Slower enrollment or event accrual can also increase development timelines and costs without guaranteeing successful outcomes.
Bristol-Myers Squibb News
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $42.52 and its highest was $68.64 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $136.88B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Oct 29, 2026 which is in 66 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Jul 30, 2026. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.597 by $0.443.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.63 which represents an annual dividend yield of 3.75%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.72.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,042,714,600 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $2.04 in its last earnings report, beating expectations of $1.597. Following the earnings report the stock price went up 2.789%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in BMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bristol-Myers Squibb Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$67.28 (3.95% Upside)
$67.28 (3.95% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 88%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.37%
12-Months-Change
Fundamentals
Return on Equity
3.75%
Trailing 12-Months
Asset Growth
-7.44%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
BMY Company Deck
BMY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive commercial and pipeline narrative: solid top-line growth (+5% revenue, growth portfolio +14%), multiple high-growth products (several >20% and one >80%), raised full-year guidance, strong cash generation and balance sheet, and meaningful pipeline and regulatory milestones (multiple PDUFAs, pivotal readouts upcoming). Key risks include timing delays for event-driven trials (milvexian and parts of the ADEPT program), legacy portfolio pressure from generics, an Opdivo revenue decline, and the need for improved Cobenfy dosing optimization. On balance, the highlights—strong current commercial execution, upgraded guidance, and significant pipeline/launch potential—outweigh the operational and timing challenges described.View all BMY earnings summariesBMY Revenue Breakdown
54.80% Growth Portfolio
45.20% Legacy Portfolio
BMY Stock 12 Month Forecast
Average Price Target
$67.28
▲(3.95% Upside)
Technical Analysis
Ownership Overview
0.03% Insiders
18.66% Mutual Funds
13.12% Other Institutional Investors
40.36% Public Companies and Individual Investors